N-FMOC-2-氨基茚-2-甲酸 | 135944-07-9

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - FMOC-氨基酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: N-FMOC-2-氨基茚-2-甲酸
• 英文名称: Fmoc-Aic-OH
• 英文别名: Fmoc-Aic；2-(9H-fluoren-9-ylmethoxycarbonylamino)-indan-2-carboxylic acid；FMOC-2-AMINOINDANE-2-CARBOXYLIC ACID；2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-2,3-dihydro-1H-indene-2-carboxylic acid；2-(9H-fluoren-9-ylmethoxycarbonylamino)-1,3-dihydroindene-2-carboxylic acid
• CAS: 135944-07-9
• 化学式: C₂₅H₂₁NO₄
• 分子量: 399.446
• InChiKey: MCDKTZLMNAVTIJ-UHFFFAOYSA-N

物化性质

• 熔点：
  198-202 °C
• 沸点：
  522.37°C (rough estimate)
• 密度：
  1.2390 (rough estimate)
• 溶解度：
  可溶于DMSO（轻微）、甲醇（轻微、加热）
• 稳定性/保质期：
  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 安全说明：
  S24/25
• 海关编码：
  2924299090
• 储存条件：
  密封保存在0至6°C的阴凉干燥处。

SDS

Name:	N-FMOC-2-Aminoindan-2-carboxylic acid Material Safety Data Sheet
Synonym:
CAS:	135944-07-9

Section 1 - Chemical Product MSDS Name:N-FMOC-2-Aminoindan-2-carboxylic acid Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
135944-07-9	N-FMOC-2-Aminoindan-2-carboxylic acid	ca. 100	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Keep refrigerated. (Store below 4C/39F.)

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 135944-07-9: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 198 - 201 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C25H21NO4
Molecular Weight: 399.44

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stability unknown.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 135944-07-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
N-FMOC-2-Aminoindan-2-carboxylic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 135944-07-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 135944-07-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 135944-07-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-FMOC-2-氨基茚-2-甲酸 在 吡啶 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 {2-[3-(tert-Butoxycarbonyl-{4-[tert-butoxycarbonyl-(3-tert-butoxycarbonylamino-propyl)-amino]-butyl}-amino)-propylcarbamoyl]-indan-2-yl}-carbamic acid 9H-fluoren-9-ylmethyl ester
  参考文献：
  名称：

  philanthotoxins氨基酸部分的构象限制和空间体积对AMPAR拮抗作用的影响。

  摘要：

  Philanthotoxin-343（PhTX-343）是黄蜂毒素PhTX-433的合成类似物，是离子型受体（例如AChR或iGluR）的非竞争性拮抗剂。为了确定氨基酸侧链变异的可能影响，制备了由17种PhTX-343类似物组成的文库。因此，酪氨酸被非极性，构象受限或庞大的氨基酸取代，而酰基单元和多胺部分保持不变。首次制备了具有叔酰胺基团的类似物。将五氟苯基酯用于酰胺键的形成，建立了费洛托辛溶液和固相合成的通用方案（总收率分别为39-90％和42-54％）。测试了这些类似物拮抗海藻酸盐诱导的爪蟾卵母细胞表达的大鼠脑mRNA的2-氨基-3-（3-羟基-5-甲基-4-异恶唑酰基）丙酸受体（AMPAR）的海因酸盐诱导电流的能力。这表明氨基酸部分中的空间体积被很好地耐受，并且表明与AMPAR的结合不涉及作为氢键供体的α-NHCO基团。

  DOI：

  10.1021/jm049906w
• 作为产物：
  描述：

  氯甲酸-9-芴基甲酯 、 2-aminoindan-2-carboxylic acid hydrochloride 在 sodium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 反应 2.0h， 以17%的产率得到N-FMOC-2-氨基茚-2-甲酸
  参考文献：
  名称：

  philanthotoxins氨基酸部分的构象限制和空间体积对AMPAR拮抗作用的影响。

  摘要：

  Philanthotoxin-343（PhTX-343）是黄蜂毒素PhTX-433的合成类似物，是离子型受体（例如AChR或iGluR）的非竞争性拮抗剂。为了确定氨基酸侧链变异的可能影响，制备了由17种PhTX-343类似物组成的文库。因此，酪氨酸被非极性，构象受限或庞大的氨基酸取代，而酰基单元和多胺部分保持不变。首次制备了具有叔酰胺基团的类似物。将五氟苯基酯用于酰胺键的形成，建立了费洛托辛溶液和固相合成的通用方案（总收率分别为39-90％和42-54％）。测试了这些类似物拮抗海藻酸盐诱导的爪蟾卵母细胞表达的大鼠脑mRNA的2-氨基-3-（3-羟基-5-甲基-4-异恶唑酰基）丙酸受体（AMPAR）的海因酸盐诱导电流的能力。这表明氨基酸部分中的空间体积被很好地耐受，并且表明与AMPAR的结合不涉及作为氢键供体的α-NHCO基团。

  DOI：

  10.1021/jm049906w

文献信息

• [EN] ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS<br/>[FR] DÉRIVÉS FUSIONNÉS D'ACIDE CYCLOPENTANE-CARBOXYLIQUE À SUBSTITUTION ACYLAMINO, ET LEUR UTILISATION COMME PRODUITS PHARMACEUTIQUES
  申请人：SANOFI AVENTIS

  公开号：WO2009135590A1

  公开（公告）日：2009-11-12

  The present invention relates to compounds of the formula (I), wherein A, Y, Z, R3 to R6, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula (I), their use and pharmaceutical compositions comprising them.

  本发明涉及具有式(I)的化合物，其中A，Y，Z，R3至R6，R20至R22和R50具有权利要求中指出的含义，它们是有价值的药物活性化合物。具体而言，它们是内皮分化基因受体2（Edg-2，EDG2）的抑制剂，该受体可被溶血磷脂酸（LPA）激活，也被称为LPA1受体，并且可用于治疗例如动脉粥样硬化、心肌梗死和心力衰竭等疾病。本发明还涉及制备式(I)化合物的方法、它们的使用以及包含它们的药物组合物。
• 2-Substituted-1 H-benzimidazile-4-carboxamides are PARP inhibitors
  申请人：Zhu Gui-Dong

  公开号：US20060229351A1

  公开（公告）日：2006-10-12

  Compounds of Formula (I) inhibit the PARP enzyme and are useful for treating a disease or a disorder associated with PARP. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I), method of treatment comprising compounds of Formula (I), and methods of inhibiting the PARP enzyme comprising compound of Formula (I).

  公式（I）的化合物抑制PARP酶，可用于治疗与PARP相关的疾病或紊乱。还披露了包括公式（I）化合物的药物组合物、包括公式（I）化合物的治疗方法，以及包括公式（I）化合物的抑制PARP酶的方法。
• Development of Highly Potent Inhibitors of Ras Farnesyltransferase Possessing Cellular and <i>in Vivo </i>Activity
  作者：Katerina Leftheris、Toni Kline、Gregory D. Vite、Young H. Cho、Rajeev S. Bhide、Dinesh V. Patel、Manorama M. Patel、Robert J. Schmidt、Harold N. Weller、Mary L. Andahazy、Joan M. Carboni、Johnni L. Gullo-Brown、Francis Y. F. Lee、Carol Ricca、William C. Rose、Ning Yan、Mariano Barbacid、John T. Hunt、Chester A. Meyers、Bernd R. Seizinger、Robert Zahler、Veeraswamy Manne

  DOI：10.1021/jm950642a

  日期：1996.1.1

  Analogs of CVFM (a known nonsubstrate farnesyltransferase (FT) inhibitor derived from a CA1A2X sequence where C is cysteine, A is an aliphatic residue, and X is any residue) were prepared where phenylalanine was replaced by (Z)-dehydrophenylalanine, 2-aminoindan-2-carboxylate, 1,2,3,4-tetrahydroisoquinoline-3-carboxylate (Tic), and indoline-2-carboxylate. The greatest improvement in FT inhibitory potency

  制备了CVFM（衍生自CA1A2X序列的已知非底物法尼基转移酶（FT）抑制剂的类似物，其中C为半胱氨酸，A为脂族残基，X为任何残基），其中苯丙氨酸被（Z）-脱氢苯丙氨酸，2-氨基茚满取代-2-羧酸盐，1,2,3,4-四氢异喹啉-3-羧酸盐（Tic）和二氢吲哚-2-羧酸盐。对于Tic衍生物（IC50 = 1 nM），观察到了FT抑制能力的最大改善。然而，该化合物在阻断致癌Ras诱导的NIH-3T3成纤维细胞转化方面无效。制备了其中并入了Cys-Val亚甲胺等排体和Tic替代物的化合物。该衍生物抑制FT的IC50为0.6 nM，并且在5 microM时抑制了稳定转化的NIH-3T3成纤维细胞的不依赖贴壁的生长。用叔丁基取代该衍生物的A1侧链，并用谷氨酰胺取代X位置，得到的衍生物的IC50为2.8 nM，EC50为0.19 microM，比（S *，R * ）-N-[[2- [N-（2-氨基-3-巯基丙基）-L-戊基]
• Potent α4β1 Peptide Antagonists as Potential Anti-Inflammatory Agents
  作者：David Y. Jackson、Clifford Quan、Dean R. Artis、Thomas Rawson、Brent Blackburn、Martin Struble、Geraldine Fitzgerald、Kathryn Chan、Sheldon Mullins、J. P. Burnier、Wayne J. Fairbrother、Kevin Clark、Maureen Berisini、Henry Chui、Mark Renz、Susan Jones、Sherman Fong

  DOI：10.1021/jm970175s

  日期：1997.10.1

  migration, adhesion, and subsequent extravasation of leukocytes into inflamed tissues contribute to the pathogenesis of a variety of inflammatory diseases including asthma, rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. The integrin adhesion receptor alpha 4 beta 1 expressed on leukocytes binds to the extracellular matrix protein fibronectin and to the cytokine inducible vascular

  白细胞向发炎组织的迁移，粘附和随后的外渗促成多种炎性疾病的发病机理，包括哮喘，类风湿性关节炎，炎性肠病和多发性硬化症。在白细胞上表达的整联蛋白粘附受体α4 beta 1在发炎部位与细胞外基质蛋白纤连蛋白和细胞因子诱导的血管细胞粘附分子-1（VCAM-1）结合。α4 beta 1与VCAM-1的结合可引发白细胞与血管内皮的牢固粘附，然后渗入组织。针对alpha 4 beta 1或VCAM-1产生的单克隆抗体可以在多种动物模型中缓解这种炎症反应。最近，含有基于纤连蛋白连接节段1（CS-1）的共有LDV序列的肽和含有RCD基序的环状肽已显示出有望通过阻断α4 beta 1与VCAM-的相互作用来调节白细胞迁移和炎症。 1。在这里，我们描述了新颖，高效的环状肽，它们在亚纳摩尔浓度下竞争性抑制α4β1与VCAM-1和纤连蛋白的结合。代表性类似物的结构通过NMR光谱法确定，并用于促进肽前导的优化。本文
• Peptidomimetics in the Discovery of New Insect Growth Regulators: Studies on the Structure−Activity Relationships of the Core Pentapeptide Region of Allatostatins
  作者：Zhen-peng Kai、Yong Xie、Juan Huang、Stephen S. Tobe、Jin-rui Zhang、Yun Ling、Li Zhang、Yi-chen Zhao、Xin-ling Yang

  DOI：10.1021/jf200085d

  日期：2011.3.23

  the complete core region. Furthermore, compound I3 has a clear effect in vivo on juvenile hormone (JH) biosynthesis of Diploptera punctata females, providing a possible application for cockroach management. On the basis of the structure−activity relationship of pentapeptide analogues, a general structure of potential potent AST analogues is proposed here. A new approach using peptidomimetics in the discovery

  在蟑螂中发现蟑螂型allatostatin（ASTs）具有抑制体集（CA）产生幼体激素的能力。的AST被认为是潜在的昆虫生长调节剂（IGR）的候选，但有几个缺点，包括不存在的作用在体内和快速降解体内，因此无法将其应用在害虫管理中。选择CA作为靶标，并选择核心五肽区（YDFGL）作为基于Allatostatin搜索新IGR的前导序列。我们设计并合成了24个类似物，它们模仿了核心区域的每个氨基酸，以确定结构与活性之间的关系以及在保持活性的同时缩短核心区域中AST的可能性。结果表明，该序列FGLa比Y / FX更重要，因为Y / FX模仿表现出强烈的影响在体外和体内。特别地，化合物I3是通过用6-苯基己酸取代Y / FX而合成的，并且在体外表现出更高的活性。而不是完整的核心区域。此外，化合物I3在体内对点状双翅目雌性的幼体激素（JH）生物合成具有明显作用，为蟑螂管理提供了可能的应用。基于五肽类似